Last updated: May 28, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT03941756 | — | Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma | Unknown mechanism |
| NCT06066138 | 1 | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | PD-L1 -- immune checkpoint inhibitor (atezolizumab) |
| NCT05053555 | — | High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies | Unknown mechanism |
| NCT05498792 | 1 | Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma | FACT complex modulator CBL0137 + CTLA-4 + PD-1 -- small molecule + immune checkpoint inhibitors |
| NCT05225428 | — | Video Education With Result Dependent dIsclosure | Unknown mechanism |
| Sponsor | Recruiting trials |
|---|---|
| M.D. Anderson Cancer Center | 18 |
| H. Lee Moffitt Cancer Center and Research Institute | 8 |
| Vastra Gotaland Region | 7 |
| National Cancer Institute (NCI) | 7 |
| Xijing Hospital | 5 |
Countries/regions with the most active trial sites for melanoma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Aug 31, 2026 | NCT07444606 | Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases | Oncolytic adenovirus -- oncolytic viral therapy (DNX-2401) |
| Aug 31, 2026 | NCT07414979 | Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma | Tumor antigens -- adoptive CD8+ antigen-specific T cell therapy |
| Aug 1, 2026 | NCT07581509 | Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma | PD-1 -- immune checkpoint inhibition (monoclonal antibody) |
| Jun 30, 2026 | NCT07518043 | A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors | PD-1 -- immune checkpoint inhibitor biosimilar (monoclonal antibody) |
| Jun 19, 2026 | NCT07475572 | A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma | PD-1 -- immune checkpoint inhibitor (monoclonal antibody biosimilar) |
| Jun 1, 2026 | NCT07476326 | Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma | PD-1 -- immune checkpoint inhibitor (nivolumab biosimilar Bmab1700 and Opdivo) |
| Jun 2026 | NCT07389525 | Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study | Immune checkpoint inhibitors -- immune checkpoint blockade (monoclonal antibodies) |
| May 1, 2026 | NCT07237594 | IL-17 Blockade to Decrease irAEs (REPLAY) | IL-17A -- monoclonal antibody (Secukinumab) |
You've seen the melanoma landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.